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Transcriptional regulationHistone post-translationalmodiﬁcation is a key step thatmay result in an epigeneticmark that regulates chroma-
tin structure and gene transcriptional activity thereby impacting many fundamental aspects of human biology.
Subtypes of post-translational modiﬁcation such as acetylation andmethylation are executed by a variety of dis-
tinct modiﬁcation enzymes. The cytoplasmic and nuclear concentrations of these enzymes are dynamically and
tightly controlled at the protein level to precisely ﬁne-tune transcriptional activity in response to environmental
clues and during pathophysiological states. Recent data have emerged demonstrating that the life span of these
critical nuclear enzymes involved in histone modiﬁcation that impact chromatin structure and gene expression
are controlled at the level of protein turnover by ubiquitin–proteasomal processing. This review focuses on the
recent progress on mechanisms for ubiquitin–proteasomal degradation of histone modiﬁcation enzymes and
the potential pathophysiological signiﬁcance of this process.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Histone proteins are a group of nuclear proteins including histone
H1, H2A, H2B, H3 and H4. Two sets of histone H2A, H2B, H3 and H4
form an octameric core; the core and the surrounding ~147 base pairs
of genomic DNA comprise the basic structural unit referred to as the
nucleosome. Notably, histone NH2-terminal tails are free from the nu-
cleosome core structure. The primary composition of the histone NH2-
terminus makes it prone to targeting by a variety of post-translational
chemical modiﬁcations [1–5]. Well-recognized histone modiﬁcations
include acetylation [6,7], methylation [8,9], ubiquitination [10], phos-
phorylation [11], sumoylation [12], ADP-ribosylation [13], and recently
O-palmitoylation [14,15]. Histone post-translational modiﬁcations
are catalyzed by enzymatic processes. These enzymes catalyze the
covalent attachment of moieties to vulnerable residue(s) of histone
NH2-terminal tails [6,8–11]. For example, histone acetyltransferases
speciﬁcally catalyze histone acetylation by addition of an acetyl group
to the lysine residue of the histone, while histone methyltransferases
add a methyl group to lysine or arginine residues of histones. The
complexities of modiﬁcation of histones continue to expand as are theh, Pulmonary, Allergy, & Critical
ﬁore, NW 628, Pittsburgh, PA
0.
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ights reserved.enzymes that catalyze these activities, yet there is little known regard-
ing control mechanisms that govern availability of histone related
enzymes.
Histone protein modiﬁcations can occur simultaneously within
different acceptor residues of one histone or among different histone
proteins [16]. Analyses of calf histones using peptide mass ﬁngerprint-
ing mass spectrometry identiﬁed numerous concurrent modiﬁcations.
For example, methylation, acetylation, and ubiquitination within his-
tone proteins have been identiﬁed revealing 13 modiﬁcation sites in
histone H2A, 12 modiﬁcation sites in histone H2B, 21 modiﬁcation
sites in histone H3, and 14 modiﬁcation sites in histone H4 [17,18]. No-
tably, themost common acceptor sites within histone are located in his-
tone NH2-terminal free tails, although residues residing within the core
structures can be alsomodiﬁed. Histonemodiﬁcations are also dynamic
and reversible [16]. For example, lysine residues can be modiﬁed by
lysine acetyltransferases (KATs) or lysine methyltransferases (KMTs),
and subsequently these groups can be removed by actions of lysine
deacetylatases (HDACs) and lysine demethylases (KDMs). Histone
modiﬁcations are recognized by other histone modiﬁers that contain
speciﬁc recognition binding domains that elicit functional operations.
In this regard, histone modiﬁcation enzymes can recruit transcription
factors during assembly of functional complexes that regulate chroma-
tin structure and transcriptional activity. Therefore, histone modiﬁca-
tion enzymes can interact coordinately and synergistically.
Histone post-translationalmodiﬁcations impact chromatin-templated
processes such as gene transcription, DNA replication, and DNA repair.
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chromatin architecturewith regard to an active (euchromatin) or inactive
(heterochromatin) state that is linked to gene transcriptional activation,
or gene repression, respectively. In general, histone acetylation opens
the chromatin structure that increases gene transcription, whereas
histone methylation condenses chromatin that inhibits gene activation
[5,6]. For example, histone acetylation at H3K14 increases gene transcrip-
tion, whereas histone H3 methylation inhibits gene activation. Hence,
there appears to be a delicate balance between various epigenetic modi-
ﬁcations on histone proteins that modulates gene transcriptional activity
in responding to the environmental pathophysiological stimuli. These
post-translational modiﬁcations on histones regulate diverse processes
including development, differentiation, cell proliferation, and innate
immunity relevant to acute and chronic diseases.
Histone modiﬁcation is also regulated in response to a variety of
environmental clues. There appears to exist a coordinate level of alter-
ations in degree of protein modiﬁcation within a histone that reﬂects
changes in the type or magnitude of some stimuli [5,6]. In this manner,
it is reasonable that there also exists an appropriate similar pattern of
expression or activities of regulated histone modiﬁers. The factors that
control concentrations of nuclear histone modiﬁcation enzymes may
be critical therefore in regulating gene expression. However, limited
information is available regarding molecular processes that control
availability of these histone modiﬁers. Among various regulatory pro-
cesses, the ubiquitin proteasomal system (UPS) is a universal pathway
that controls steady-state protein levels in eukaryotes. Here, we will
focus on the recent progress identifying the ubiquitin–proteasomal
machinery as a key mechanism that governs the availability of histone
modiﬁcation enzymes thereby impacting gene expression (Table 1).
2. The protein degradation via the ubiquitin–proteasome
Protein concentrations are tightly controlledwithin living cells, with
the UPS degrading the bulk of intracellular proteins (Fig. 1). The target
protein destined for degradation is usually covalently labeled with
monoubiquitin or polyubiquitin moieties [19,20]. Ubiquitin is a 76
amino acid (aa) protein that is highly conserved among all eukaryotes
and is expressed in almost all cell types. Ubiquitination of a targeted
protein involves several energy consuming enzymatic reactions [21,22].
First, an E1 ubiquitin-activating enzyme recruits and transfers ubiquitin
to an E2 ubiquitin-conjugating enzyme. The terminal reaction involves
interaction between anE2 ubiquitin-conjugating enzymewith a speciﬁc
E3 ubiquitin ligase that coordinates ligation of the ubiquitin moiety to a
target substrate via an isopeptide linkage between the COOH group of
the carboxyl terminus in ubiquitin and the ε-amino group of a lysineTable 1
Histone modiﬁcation enzymes that are degraded by the ubiquitin–proteasomal system.
Enzyme Histone substrates Cellular process invol
p300/
CBP
H2A K (5); H2B K (5, 12, 15, 20); Chromatin regulation
H3K (14, 18, 23, 56); H4K (5, 8, 12) Transcription activati
PCAF H3K (14), H4 (nucleosome) Transcription activati
GCN5 H2B K (11,16), H3K (9, 14, 18, 23, 27, 36), H4K (8,16),
H2A–Z
Transcription activati
assembly
HBO1 DNA replication
MORF4 Unknown Cell senescences
MORF4L1 H2A, H4 Transcription activati
SRC1 H3K (9,14) Transcription activati
HDAC1 H2A, H2B, H3, H4 Transcription repress
HDAC2 H2A, H2B, H3, H4K16 Transcription repress
DNMT1 DNA CpG Transcription repress
Lpcat1 H4 (ser47) Transcription repressresidue of the targeted protein. Among the human genome, there is
only one E1, but fourteen E2s, and more than one thousand E3s. The
E3 ubiquitin ligase is substrate-speciﬁc, and yet one E3 ligase may
control the degradation of numerous substrate proteins [23]. On the
other hand, one protein could be ubiquitinated by more than one E3
ubiquitin ligase [24]. The precise targets for the majority of the E3
ubiquitin ligases remain largely unknown. Nevertheless, research into
the molecular behavior of components within ubiquitin E3 ligases re-
main an area of high interest as they appear to regulate histonemodiﬁ-
cation enzymes.
Molecular recognition signals exist in many proteins that recruit
ubiquitin E3 ligase complexes. The targeted protein for degradation is
usually modiﬁed before binding to an E3 ubiquitin ligase, and these
modiﬁcations often involve phosphorylation, dephosphorylation, acety-
lation, or methylation [23,25–27]. Cellular compartmentalization of
proteins is a critical issue with regard to function, and both cytoplasmic
or nuclear localization of the targeted protein can be directed through
ubiquitination by distinct E3 ubiquitin ligases. The E3 ubiquitin ligases
distribute in both the cytoplasmic and nuclear compartments. For
example, one ubiquitin E3 ligase component, termed F-box protein
FbxW1 (β-transducin repeat-containing protein, β-TrCP), exists as
two isoforms: FbxW1-1 and FbxW1-2. These isoforms differ in localiza-
tion in the cells,with the FbxW1-2 isoformpresent in the cytoplasmand
FbxW1-1mainly identiﬁed in the nucleus [27,28]. Ubiquitination is also
a reversible enzymatic reaction as this moiety can be removed from a
protein by deubiquitination enzymes [29].
Polyubiquitinated proteins are degraded by a large proteasome
complex (2.5 MDa), that consists of a 20S core particle and one or two
19S regulatory particles [19,20]. The 20S core particle contains 28
proteins containing α and β subunits forming an α–β–β–α-four-layer
cylindrical structure. Each layer is comprised of 7 subunits, the beta
subunits of the 20S core particle display protease activity, hydrolyzing
the targeted proteins into 5–11 aa pieces in the lumen of the 20S core
particle [30]. The 19S regulatory particle “caps” the two sides of the
20S core particle, which is easily dissociated from the20S core structure.
It is believed that several subunits in the lid of the 19S regulatory parti-
cle speciﬁcally bind to the ubiquitin chain, functioning to recognize and
capture ubiquitinated proteins. The base subunits unfold, direct, and
pass the protein into the proteolytic lumen of the 20S core. The UPS
degrades proteins both in the cytoplasm and in the nucleus. It appears
that the proteasome is located in close proximity to subcellular sites of
massive protein degradation. Indeed, proteasomal structures are identi-
ﬁed in both the cytoplasm near the endoplasmic reticulum and within
the nucleus in the centrosome [31,32]. In neuronal exons, proteasomal
localization is determined by a 19S lid subunit that speciﬁcally bindsved E3 ligase Disease relevance Reference
FbxO3,
Mdm2
Epithelial cancers, myeloid leukemias [43,68,69]
on BRMS1 Rubinstein–Taybi syndrome 2
on MDM2 [34]
on chromatin CRL4 [56]
FbxW15
(L17)
[44]
Unknown [45]
on Nedd8 Breast cancer, coronary artery disease [83]
on Unknown Rhabdomyosarcoma [87]
ion Mdm2, Chfr Colon cancer, COPD [39,99]
ion RLIM Cancer, COPD [35,100]
ion Cdh1, UHRF1 Hereditary sensory neuropathy,
deafness
[36,106]
ion FbxW1 Lung cancer, ALI [37]
Fig. 1. Schematic representation of protein turnover via the ubiquitin proteasome system. The protein destined for ubiquitin proteasomal degradation is polyubiquitinated that involves
multi-step enzymatic processes. The targeted protein for degradation is usually post-translationally modiﬁed (red circles) by a post-translational modiﬁcation (PTM) enzyme that
facilitates E3 ubiquitin ligase binding. Ubiquitin (yellow circles) isﬁrst loaded onto an E1ubiquitin activation enzyme in anATP-dependentmanner, and then transferred to E2 conjugation
enzyme. An E3 ubiquitin ligase interactswith the E2 conjugation enzyme and the targetedprotein substrate. The E2ubiquitin conjugation enzyme then covalently attaches the ubiquitin to
the histone modiﬁcation enzyme via an isopeptide linkage. The polyubiquitin chain of the protein is recognized by the lid of 19S regulatory particle and escorted into 20S core for
degradation. The β-subunits of 20S core with proteolytic activity hydrolyze the targeted protein into fragments with a size of typically 5–11aa.
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enriched within speciﬁc organelles or regions by anchoring a signaling
kinase in the 19S lid [33].
3. Histone modiﬁcation enzymes are regulated by
ubiquitin proteasomal degradation
Histone modiﬁcation enzymes catalyze post-translational modiﬁca-
tions within histone particularly at the histone NH2-terminal tails that
regulate the chromatin structure and transcriptional activity. In living
cells, the chromatin structure and transcriptional activity are dynami-
cally regulated in response to clues that emergewithin pathophysiolog-
ical settings. There is mounting experimental evidence demonstrating
that the UPS plays an important role in selective degradation of histone
modiﬁcation enzymes, thus regulating a vast range of life processes
[34–40]. Various up-stream recognition signals selectively direct his-
tone modiﬁcation enzymes for UPS degradation [36,37]. Phosphoryla-
tion at certain residues of a given protein is one prerequisite for
binding of a substrate to an E3 ubiquitin ligase; this phosphorylation is
often an importantmolecular signature or phosphodegron that is recog-
nized by the ubiquitination apparatus that facilitates proteasomal deg-
radation of targeted proteins. Among various phosphodegrons, E3
ubiquitin ligase subunit FbxW1 recognizes awell-characterized binding
motif, S/TXXXS/T, within substrates. Here, the serine or threonine resi-
dues are ﬁrst phosphorylated by distinct kinases that facilitate the abil-
ity of FbxW1 to dock with the phosphorylated binding motif leading to
substrate ubiquitination [23]. For example, the histone O-palmitoylation
enzyme Lpcat1 is proteosomally degraded, a process involving its phos-
phorylation [41]. In other modes of regulation, dephosphorylation in
some cases is a signal that leads toUPS degradation. For example, dephos-
phorylation of the acetyltransferase, p300, at Ser1834 triggers its UPS
degradation [41]. However, Akt-mediated p300 phosphorylation at
Ser1384 stabilizes it from degradation [42]. Further, acetylation or methyl-
ation also modulates vulnerability of histone modiﬁcation enzymes
for UPS degradation. In addition, acetylation of MORF4L1, an acetyltrans-
ferase, stabilizes it from UPS degradation (unpublished observations).
Conversely, methylation of the DNA methyltransferase DNMT1 acts as a
degron that destabilizesDNMT1 [36]. Thus, histonemodiﬁcation enzymes
themselves aremarked by a variety of the post-translational alterations atspeciﬁc residues that selectively target these enzymes for UPS degrada-
tion. These targeting processes are triggered by speciﬁc environmental
stimuli, thus precisely controlling histone modiﬁcation enzyme availabil-
ity within cells that can alter chromatin architecture and transcriptional
activity.
In general, histonemodiﬁcation enzymes are distributed both in the
cytoplasm and in the nucleus (Fig. 2) and accordingly histonemodiﬁca-
tion enzymes are degraded in the cytoplasm and in the nucleus
[34–40,43,44]. Rapid turnover of these enzymes appears essential to
reprogram chromatin architecture and transcriptional activity in
response to various stimuli. It is conceivable that turnover of histone
modiﬁcation enzymes in the nucleus is a cellular homeostatic control
mechanism that efﬁciently removes enzymes from chromatin, limits
their association with transcriptional factors, or restricts their associa-
tion with co-activators to tightly regulate chromatin architecture and
transcriptional activity.
Many histone modiﬁcation enzymes are also degraded in the cyto-
plasm [43–45]. UPS degradation of histone post-translational enzymes
may reduce the total cellular mass of any individual enzyme that indi-
rectly regulates histonemodiﬁcation by nuclear forms. Second, turnover
of the cytoplasmic histone modiﬁcation enzymes may regulate cyto-
plasmic functions of these histone modiﬁcation enzymes. Cytoplasmic
histone modiﬁcation enzymes may represent a storage pool that is
also functional. In this regard, histone modiﬁcation enzymes catalyze
post-translational modiﬁcation of cellular proteins other than histones.
For example, p300 acetylates more than seventy cellular proteins other
than histone proteins, including control of p53 stability in the cytoplas-
mic compartment [46]. Turnover of cytoplasmic p300will terminate the
acetylation-dependent regulation of these cellular proteins that may
affectmany biological processes. Third, turnover of histonemodiﬁcation
enzymes in the cytoplasmmay impact nucleosome assembly and aggre-
gation. For example, histone proteins are post-translationally modiﬁed
in the cytoplasmic compartment before the histones enter into the
nucleus for their nucleosomal assembly [47]. Thus, it is conceivable
that UPS degradation of a histone modiﬁcation enzyme may regulate
nucleosome assembly and aggregation, although this appears specula-
tive at present.
Finally, histone modiﬁcation enzymes reversibly shuttle between
the nucleus and cytoplasm and this is tightly coordinated with histone
Fig. 2. The ubiquitin proteasome system spatially degrades histone modiﬁcation enzymes to regulate gene transcriptional activity. Histone modiﬁcation enzymes are ubiquitinated and
proteosomally degraded in the cytoplasm or in the nucleus. Degradation of histonemodiﬁcation enzymes in the cytoplasm limits themass of the enzyme that may enter into the nucleus
but also modulates the cytoplasmic function of the enzyme. Rapid elimination of a histonemodiﬁcation enzyme in associationwith chromatin in the nucleus limits the extent of a histone
modiﬁcation and may result in a shift in transcriptional expression of genes in response to an environmental stimulus. In some cases, the histone modiﬁcation enzymes shift into the
cytoplasmic compartment for ubiquitination. Ubiquitin–proteasomal turnover of histone modiﬁcation enzymes terminates their function impacting transcriptional activity.
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cation enzymes can translocate from the nucleus into the cytoplasm
for ubiquitination thereby preventing the enzyme from exerting impor-
tant epigenetic roles [48].
4. Ubiquitin proteasomal degradation of histone
modiﬁcation enzymes
4.1. GCN5 (general control non-derepressible 5)
Histone acetyltransferases (HATs) are a group of histone modiﬁca-
tion enzymes that attach an acetyl group to the ε-amino group of lysine
residues of histones or other proteins. Histone NH2-terminal tail
acetylation relaxes the chromatin structure near promoter regions to
activate gene transcription. HATs include more than 100 members
categorized into at least several subfamilies, the GCN5-related N-
acetyltransferases (GNATs); p300/CREB-binding protein (CBP) and
p300/CBP-associated factor (PCAF); the MYST proteins that includeHBO1 (histone acetyltransferase binding to origin recognition com-
plex), an acetyltransferase that modulates DNA replication origin
licensing; others include the general transcription factor HATs including
the TFIID subunit TBP-associated factor-1 (TAF1), and the nuclear
hormone-related HATs, SRC1 and ACTR (SRC3).
Histone acetyltransferase general control non-derepressible 5 (GCN5)
globally acetylates the histone NH2-terminal free tail at several molecular
sites including H3K14, H4K8, and H4K16, thus linking the acetyltransfer-
ase to transcriptional activation. In Saccharomyces cerevisiae, GCN5
is active as a component in the histone acetylation protein complex
containing the Spt-Ada-GCN5 acetyltransferase complex (SAGA) [49],
Saga altered Spt8 absent acetyltransferase complex (SALSA) [50], and
GCN5/Ada acetyltransferase complex (Ada) [51] that exhibit distinct
functions. The GCN5/SAGA complex exerts acetyltransferase activity in-
volved in RNA polymerase II-dependent transcriptional regulation that
is required for recruitment of the basal transcription machinery to the
promoter. GCN5/SAGA activity regulates acetylation of nucleosomes at
H2B, and histone H3 (K9, 14, 18, and 23) [52,35]. In the SAGA complex,
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GCN5/SALSA is a distinct complex that stimulates gene transcription
[52]. GCN5/Ada complex selectively catalyzes histone H3 (K14, 18)
and H2B acetylation leading to transcriptional activation [52]. GCN5
is involved in diverse cellular processes including proliferation
and tumorigenesis [53–55]. Interestingly, GCN5 itself is unstable and
ubiquitinated in human cancer cells [56]. Inhibition of the proteasome
by addition of a proteasomal inhibitor, MG132, stabilizes GCN5 protein
levels. Cullin4-RING E3 ubiquitin ligase (CRL4) cellular depletion by
siRNA results in stabilization of GCN5 levels whereas overexpression of
CRL4 reduces GCN5 protein levels [56]. CRL4 is sufﬁcient to ubiquitinate
GCN5 both in vivo and in vitro. Interestingly, acidic nucleoplasmic DNA
binding protein 1 (And-1) that is elevated in tumorogenic cells impacts
GCN5 protein stability. And-1 and CRL4 competitively bind to the
carboxyl-terminus of GCN5 [56]. And-1 stabilizes GCN5 by impairing
the interaction between GCN5 and CRL4 thereby preventing GCN5
ubiquitination and degradation. The ubiquitination acceptor site within
the GCN5 molecule has not yet been identiﬁed, nor does the upstream
signal that triggers CRL and GCN5 binding to modulate acetylation
in vivo.
4.2. p300/CBP (CREB-binding protein)
The p300/CBP proteins are a sub-family of histone acetyltransferases
that catalyze global acetylation of lysine residues in histone proteins
H2AK5, H2B (K5, K12, K15, K20), H3 (K14, K18, K23), and H4 (K5, K8,
K12). p300/CBP also acetylates histones inside the core structures,
speciﬁcally histone H3 at K56. Aside from histone proteins, p300/CBP
selectively acetylates more than 70 transcriptional regulators [57].
p300/CBP mediated histone NH2-terminal tail acetylation relaxes the
chromatin structure in the promoter region to activate gene transcrip-
tion. The p300/CBP complex also recruits the basal transcriptional
machinery to the promoter region and acts as an adaptor molecule to
bind multiple proteins to regulate transcriptional activity [58]. p300/CBP
factors participate in many pathophysiological processes including cell
proliferation [59], development [60], tumorogenesis [61], and apoptosis
[62].
Several signaling pathways have been identiﬁed that regulate p300
turnover. UPS degradation of p300 was ﬁrst reported in human cardiac
myocytes that were exposed to doxorubicin [63]. Mitogen-activated
protein kinases (MAPK) including p38, and other kinases such as Ras
and Akt induce phosphorylation of p300 to regulate proteasome-
mediated p300 degradation [43,64–66]. In contrast to the mechanism
of phosphorylation mediated protein degradation, dephosphorylation
of p300 at Ser1834 triggers p300 UPS degradation. Speciﬁcally, the
B56γ3 (PPP2R5C) regulatory subunit of protein phosphatase 2A
(PP2A) targets p300 for degradation through the 26S proteasomal path-
way in the nucleus [41]. Reciprocally, Akt catalyzed phosphorylation at
Ser1834 stabilizes p300 [66]. Interestingly, cytosolic p300 exhibits ubiq-
uitin E3 ligase activity itself particularly with regard to p53 protein sta-
bility and signal transduction [67]. Several E3 ubiquitin ligases are
involved in p300 turnover in response to distinct upstream signals.
The E3 ubiquitin ligase Fbxo3 mediates p300 degradation which forms
a complex with PML, Skp1, Cullin 1 and p300 [68]. One study demon-
strated a previously unrecognized role of E3 ligase function of the breast
cancermetastasis suppresser 1 (BRMS1) protein on histone acetyltrans-
ferase p300 stability [69]. BRMS1 induces polyubiquitination and
proteasome-mediated degradation of p300. BRMS1 appears to belong
to a bacterial IpaH E3 ligase family with an evolutionarily conserved
CXD motif that may be responsible for its E3 ligase function. Mutation
of this E3 ligase motif abolishes BRMS1-induced p300 polyubiquitination
and degradation [69]. Levels of p300 are tightly and spatially regulated
to maintain normal cellular homeostasis through UPS degradation.
p300/CBP is degraded both in the cytoplasm and in the nucleus but via
distinct mechanisms. For example Fbxo3 mediates p300 turnover in the
nucleus [68]. p300 also shuttles from the nucleus into the cytoplasm forubiquitination [48]. The degradation of CBP is less studied. The upstream
signals that trigger CBPdegradation are not known, nor is the E3ubiquitin
ligase(s) that might modulate CBP lifespan in cells. Interestingly, one
study reported that promyelocytic leukemia (PML) nuclear bodies appear
to be linked to UPS degradation of CBP [70].4.3. PCAF (p300/CREB-binding protein-associated factor)
PCAF was ﬁrst reported as a protein that interacts with CBP. PCAF
contains intrinsic histone acetyltransferase activity and functions as a
coactivator for a number of transcriptional activators [71]. PCAF exhibits
histone acetyltransferase activity that potentially acetylates free histone
H3, histone H4, and nucleosomal H3 and other transcription factors to
regulate transcriptional activity. Yeast PCAF forms multi-subunit
protein complexes with several transcription factors including TATA
box-binding protein-associate factors and GCN5 to exert its histone
modiﬁcation functions. PCAF has been proposed to facilitate long-
distance transcriptional enhancement by direct association with
enhancer sequences and interacts with actin and RNA polymerase II to
maintain efﬁcient transcriptional elongation. PCAF plays a role in
transcriptional activation, cell cycle progression, and cellular differenti-
ation. PCAF is regulated by Mdm2 mediated UPS degradation [34]. E3
ubiquitin ligase Mdm2 ubiquitinates the NH2-terminus of PCAF in vitro
and in cells. PCAF ubiquitination occurs in the nucleus, as MDM2 devoid
of its nuclear localization signal is unable to degrade nuclear PCAF. PCAF
levels are higher in Mdm2-deﬁcient mouse embryonic ﬁbroblast (MEF)
cells compared to Mdm2-containing MEF cells, indicating that Mdm2
regulates the stability of PCAF by ubiquitin proteasomal processing. In
addition, PCAF has intrinsic E3 ubiquitin ligase activity to regulate
protein stability.4.4. HBO1 (histone acetyltransferase binding to origin recognition complex)
HBO1 is amember of theMYST histone acetyltransferase family that
modulates cell cycle progression and proliferation through epigenetic
mechanisms [72–75]. In mammals, HBO1 associates with Mcm2-7
helicase, cdc6, and Cdt1 to constitute the origin recognition complex
[74]. HBO1 may also interact with ING5 and JADE1 to form a complex
to regulate cell proliferation and cell survival [75]. HBO1 acetylates
histone H3 at H3K14 and histone H4 to load the origin recognition
complex onto chromatin to initiate DNA replication licensing and
trigger DNA replication during the late G1 phase. Knockdown of HBO1
by speciﬁc shRNA results in reduced S phase entry and cell death,
conﬁrming the pivotal function of HBO1 in initiation of DNA synthesis
and cell proliferation [44]. Despite the importance of HBO1's function
in DNA replication, the regulation of HBO1 protein level in cells is less
studied. One recent study identiﬁed that HBO1 is a short lived protein
with a half-life of approximately 3 h [44]. HBO1 is UPS degraded evi-
denced by its stabilization after exposure to the proteasome inhibitor,
MG132. A relatively uncharacterized ubiquitin E3 ligase component,
Fbxw15, directly interacts with HBO1 to mediate its ubiquitination at
K338. As opposed to its predicted role in regulating epigenetic functions
in the nucleus, HBO1 degrades predominantly in the cytoplasmic com-
partment raising the possibility of nuclear–cytoplasmic cross-talk
in regulation of HBO1 lifespan. Fbxw15 mediated HBO1 degradation
requires mitogen-activated protein kinase 1 (Mek1), which triggers
HBO1 phosphorylation and degradation in epithelial cells. Disruption
of Fbxw15 by silencing blocksMek1 ability to trigger HBO1 degradation
[44]. Modulation of Fbxw15 levels was able to differentially regulate
histone H3K14 acetylation and cellular proliferation by altering HBO1
levels. Hence, Fbxw15 is an ubiquitin E3 ligase subunit that mediates
HBO1 depletion in cells to control cell replicative capacity. The detailed
information of the molecular signals within HBO1 that regulate its
stability remains unknown.
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Most histone acetyltransferases activate transcriptional activity and
promote cell proliferation. In contrast, MORF4 was ﬁrst cloned as a
senescence gene from human chromosome 4 [76,77]. Introduction of
MORF4 into cells causes signiﬁcant cell death, although the under-
lying mechanism is unknown. There are three members of the MORF4
protein family, MORF4, MORF4L1 (MRG15), and MORF4L2 (MRX)
[78–80]. Similar tomost histone acetyltransferases, MORF4L1 is a compo-
nent of the NuA4 histone acetyltransferase complex. TheMORF4L1/NuA4
complex acetylates histone proteins H2B and H4 thereby probably
impacting activation of oncogene and proto-oncogene directed transcrip-
tion. Sequence analysis indicates thatMORF4 lacks 128 aawithin its NH2-
terminus that typically contains a chromodomain; chromodomains
speciﬁcally bind to methylated lysine residues and are well conserved in
histone acetyltransferases. MORF4L1 is a multi-functional histone acetyl-
transferase that regulates senescence, apoptosis, cell cycle progression,
and DNA repair. Genome wide studies reveal that MORF4L1 is also
involved in neoplasia and atherosclerosis [81,82]. These studies suggest
that MORF4 may exert its epigenetic function by regulating a distinct
gene population fromMORF4L1 to regulate cell viability. MORF4 protein
is a short life protein with a half-life of ~30 min [45]. Addition of
MG132 accumulates MORF4, suggesting that MORF4 is degraded via the
UPS. Experimental evidence suggests that MORF4 is degraded in the
cytoplasm, because nuclear retention of this acetyltransferase extends
its lifespan in cells. Results from mass spectrometry suggest that Nedd8
may participate in MORF4L1 ubiquitination [83].
4.6. SRC-1 (steroid receptor coactivator 1)
SRC-1 is a transcriptional co-regulatory protein with intrinsic
histone acetyltransferase activity and several nuclear receptor interac-
tion domains that acetylates histone H3 and H4 [84–86]. SRC1 directly
binds to nuclear receptors and stimulates transcriptional activities in a
hormone-dependent fashion. SRC1 is recruited to promoter regions of
genes by hormones or ligand activated nuclear receptors to acetylate
histones at lysine residues to positively modulate transcriptional activi-
ty. SRC1 also recruits CBP as an adaptor to co-activate transcription [86].
SRC1 plays a central role in forming multi-subunit complexes that
remodel chromatin by recruiting a variety of transcription factors to
control the energy balancing gene population. Degradation of SRC-1 is
a UPS mediated process, as proteasomal inhibitors stabilize the protein
[87]. Themajority of SCR-1 is degraded in the cytoplasmic compartment
where SRC-1 colocalizes with proteasomal antigens [87]. SRC-1 degra-
dation is ligand-dependent and involves two degradation motifs, as
residues 2–16 corresponding to a PEST motif and residues 41–136
located in the bHLH domain of the coactivator impact protein stability
[87]. The upstream signals that trigger the protein for ubiquitination
are not yet known, nor is the E3 ubiquitin ligase involved in SRC-1
proteasomal degradation.
4.7. HDAC1 (histone deacetyltransferase 1)
Histone deacetyltransferases (HDACs) are a group of enzymes that
remove acetyl groups from modiﬁed lysine residues on histones that
results in gene transcriptional repression [88–90]. Based on their
sequence similarity, HDACs can be classiﬁed into three classes: Class I,
Class II, and Class III. Class I contains HDAC1, HDAC 2, HDAC3 and
HDAC8 which are primarily located in the nucleus. Class II HDAC en-
zymes include HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10,
which can be shuttled into the nucleus. Class III consists of Sirt 1–7.
HDAC is involved in diverse cellular processes such as control of
the cell cycle [91], cell proliferation, tumorigenesis [92], differentiation,
and development [93]. HDAC functions via the formation of largemulti-
protein complexes. For example, the HDAC-containing multiprotein
complex, Sin3, consists of six core subunits, HDAC1/2, RbAp46, RbAp48,Sin3A/Sin3B, SAP18, and SAP30 in mammalian cells [94–96]. Another
complex, NURD, consists of HDAC1/2, RbAp46, RbAp48, CHD3/CHD4
(Mi-2), MBD2/MBD3, MTA1/MTA2/MTA3, and p66α/p66 in human
[97,98].
HDACI is a Class I histone deacetyltransferase that is labile (t1/2 ~ 3 h)
anddegradedby theUPS. In the presence of the androgen receptor, the E3
ubiquitin ligase Mdm2 associates with and ubiquitinates HDAC1 at the
prostate speciﬁc antigen promoter region [39]. HDAC1 ubiquitination
requires androgen treatment and depends upon the E3 ligase activity of
Mdm2.Mdm2mediatedHDAC1UPSdegradationmay represent a reﬁned
level of regulation to terminate androgen receptor activated transcrip-
tional activity. HDAC1 also directly interacts with the carboxyl terminal
region of Chfr, an E3 ubiquitin ligasewhich functions in themitotic check-
point. Chfr ubiquitinates HDAC1 in vitro and in vivo. Overexpression of
Chfr accelerates HDAC1 degradation and this is attenuated by addition
of MG132. Chfr downregulates HDAC1 levels to stimulate p21 transcrip-
tion in cancer cells that is normally suppressed by HDAC1 [99]. Valproic
acid, an inhibitor of Class I and II HDAC enzymes, destabilizes HDAC2 by
activating Ubc8 E2 conjugating enzyme gene expression [100]. Valproic
acid-induced HDAC2 turnover critically depends on the E3 ubiquitin
ligase RLIM. RLIM speciﬁcally ubiquitinates HDAC2 for proteasomal
degradation by coordinate actions of Ubc8 and the RLIM E3 ligase [100].
Thus, polyubiquitination and proteasomal degradation through an E2–
E3 ligase interaction provide an isoenzyme-selective mechanism for
downregulation of HDAC2 protein levels. Interestingly, cigarette smoke
induces HDAC2 phosphorylation and proteasomal degradation [35].
Cigarette smoke extract exposure induces HDAC2 CKII-dependent
phosphorylation, ubiquitination, and proteasomal degradation. CKII
and proteasome inhibitors stabilize HDAC2 from its degradation.
The E3 ubiquitin ligase involved in this process has not been
identiﬁed.4.8. DNMT1 (DNA methyltransferase 1)
DNMT1 is a DNAmethyltransferase that plays a critical role in chro-
matin modiﬁcation and gene expression [101]. DNMT1 mediated DNA
methylation results in transcriptional repression and can antagonize
actions of histone acetyltransferases [102]. DNMT1 methylates CpG
residues with a preference for hemimethylated DNA [103]. Human
DNMT1plays a critical role inmaintenance of gene activity bymaintain-
ing repressed chromatin through recruitment and interaction with
histone deacetyltransferase complexes; this process modulates cell
cycle progression that may impact neoplasia [104,105]. Studies show
that DNMT1 is unstable and regulated by the UPS [105]. The HDAC
inhibitor LBH589 down-regulates DNMT1 by mediating DNMT1 UPS
degradation. The NH2-terminal 120 aa within DNMT1 are essential
for its proteasomal processing. Deletion of this fragment of DNMT1
abrogates LBH589-induced ubiquitination [105]. SET7, a histone
methyltransferase, monomethylates DNMT1 at K142 and this modiﬁed
DNMT1 is unstable and prone to proteasomal degradation [36]. In
contrast, Akt-mediated phosphorylation of DNMT1 at serine residues
stabilizes DNMT1 [36]. Cross-talk between monomethylation and
phosphorylation alter DNMT1protein levels that inﬂuenceDNA replica-
tion and S phase-G2 transition within the cell cycle [36].
At least two E3 ubiquitin ligases are involved in DNMT1 degradation.
One is Cdh1, anAPC (anaphase-promoting complex)/cyclosome ubiqui-
tin ligase. Cdh1 co-localizes with hyperphosphorylated DNMT1 in
the nucleus and ubiquitinates DNMT1, suggesting that Cdh1 degrades
DNMT1 via an unidentiﬁed phosphodegron. Depletion of Cdh1 using
siRNA increases DNMT1 levels that block 5-aza-CdR-induced degrada-
tion [40,106]. Another relevant E3 ligase is UHRF1. The protein Tip60
acetylates DNMT1 triggering ubiquitination by UHRF1, thereby targeting
DNMT1 for proteasomal degradation. In contrast, DNMT1 is stabilized
by HDAC1 and the deubiquitinase herpes virus-associated ubiquitin-
speciﬁc protease.
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Lpcat1 was initially characterized as a lung surfactant phospho-
lipid synthetic enzyme from alveolar type II epithelial cells [107].
Lpcat1 is an acyltransferase that adds a palmitate group to the
glycerol backbone of phospholipids to generate the major surfactant
lipid, dipalmitoylphosphatidylcholine. Targeted disruption of the gene
encoding Lpcat1 in mice increases newborn mortality [108]. Interest-
ingly, Lpcat1, a cytosolic protein, migrates into the nucleus to associate
and modify histone proteins for their palmitoylation to regulate tran-
scriptional activity [14,15]. Thus, Lpcat1 mediates histone lipidation as
a novel epigenetic mark. Lpcat1 is unstable with a half-life of approxi-
mately 3.5 h and it is degraded via the UPS machinery. Bacterial infec-
tion or endotoxin treatment triggers glycogen synthase kinase3-β
activation in murine lung epithelia that speciﬁcally phosphorylates
Lpcat1 at Ser178–182. This phosphorylation event stimulates recruitment
of an E3 subunit, Fbxw1. This E3 protein directly docks onto the
phosphodegron within Lpcat1 that results in Lpcat1 ubiquitination at
K221 and proteasomal degradation [37]. Lpcat1 mainly localizes in the
cytoplasmic compartment andmigrates into the nucleus upon stimula-
tion. Though FbxW1 isoforms distribute in both the cytoplasm and
nucleus, it is not clear where Lpcat1 is degraded.
5. Summary
Studies of UPS regulation of the histone modiﬁcation enzymes are
still in their infancy. Among hundreds of histonemodiﬁcation enzymes,
only a few have been fully characterized with regard to their UPS pro-
cessing. Mass-spectrometric analysis shows that many proteins are
multi-site ubiquitinated. Furthermore, because lysine residues serve as
acceptor sites for ubiquitination, acetylation, andmethylation, interplay
among these modiﬁcations increases the complexity of mechanisms
that may impact histonemodiﬁcation enzyme availability. Each residue
within these histone regulating enzymes that is covalently modiﬁed by
ubiquitinationmay impact a distinct function altering gene activity indi-
rectly after a speciﬁc pathophysiological stimulus. In the future, it will
be important to clarify howUPS targeting of these enzymes impacts cel-
lular behavior. The localization of the UPS degradation of the histone
modiﬁcation enzymes is also largely yet to be elucidated. Among the
vast array of the histone modiﬁcation enzymes, some of them are de-
graded in the cytoplasmic compartments, whereas others are degraded
in the nucleus. This may reﬂect a targeting mechanism to optimize efﬁ-
ciency to tightly control concentrations of enzymes based on the indi-
vidual needs of a cell to maintain homeostasis. The speciﬁc ubiquitin
E3 ligase or ligases that mediate ubiquitination of a speciﬁc histone
modiﬁcation enzyme also needs to be deﬁned. This latter issue is critical
as there are now emerging therapeutic entities either in preclinical or
early phase trials testing modulators of the UPS [109]. Such interven-
tions could conceivably be used as novel therapeutic strategies for
inﬂammation, cell survival, or neoplasia through altering abundance
of histone modifying enzymes.
Regulation of gene transcriptional activity requires the orchestrated
actions of a variety of histone modiﬁcation enzymes targeting the
histone NH2-terminal tails, and speciﬁc transcriptional machinery
with coregulators at targeted DNA loci. Rapid removal of these histone
modiﬁcation enzymes from the speciﬁc histone tails or DNA loci is
essential to activate or repress any given gene set. Degradation of his-
tone modiﬁcation enzymes at the protein level enables transcriptional
reprogramming in response to various stimuli depending on a speciﬁc
circumstance. There is mounting evidence supporting the UPS as a
mechanistic pathway that controls the availability of several histone
modifying enzymes that are critical in regulation of gene expression.
Hence, the UPS indirectly may alter the epigenetic code in mammalian
systems by controlling expression of genes linked to inﬂammation,
cell growth and proliferation, and survival. Deciphering the molecular
basis for UPS degradation of histone post-translational modiﬁcationenzymes in different pathophysiological settings will help us under-
stand how histonemodiﬁcation enzymes respond to signaling cascades
and exert their diverse functions. Future advances in this area might
lead to devising pharmacotherapeutic interventions directed at the
UPS to control fundamental biological processes through histone
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